<DOC>
	<DOCNO>NCT00735371</DOCNO>
	<brief_summary>The study evaluate efficacy LDX treatment group compare placebo change Baseline ADHD-RS-IV score endpoint .</brief_summary>
	<brief_title>Efficacy Safety Lisdexamfetamine Dimesylate ( LDX ) Adolescents With Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>Meet DSMIVTR criterion primary diagnosis ADHD Baseline ADHDRSIV score &gt; =28 BP w/in 95th percentile age , gender , height Subject control uncontrolled comorbid psychiatric diagnosis Subject conduct disorder Suicidal Under overweight Concurrent chronic acute illness might confound result .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>